Trade Almirall, S.A. - ALM CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.06
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.018013 %(-€3.60)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.01801%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment€1,000.00Overnight funding adjustmentCharges from full value of position-0.004209 %(-€0.84)Trade size with leverage ~ €20,000.00Money from leverage ~ $€19,000.00Go to platform: -0.00421%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: EUR
• Min traded quantity: 1
• Margin: 5.00%
• Stock exchange: Spain
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.018013 %
  (-€3.60)

• Margin. Your investment: €1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.004209 %
  (-€0.84)

Key Stats

• Prev. Close: 10.04
• Open: 10.12
• 1-Year Change: -14.67%
• Day's Range: 9.94 - 10.18

Trade Almirall, S.A. - ALM

About Almirall SA

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating agents. The Company's activities are divided into four business segments: Own network, which focuses on the commercialization of pharmaceuticals through own brand names; Licenses, which sells product rights to third parties; Research and development (R&D), which is responsible for the creation of drug candidates, as well as Dermatology, which includes sale of dermatological medicines in the United States. The Company operates through numerous subsidiaries in Europe, the Americas, Africa, Asia and Australia.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Almirall SA revenues increased 2% to EUR827.2M. Net loss totaled EUR40.9M vs. income of EUR74.3M. Revenues reflect Own Network (Spain) segment increase of 11% to EUR593.5M, Corporate segment increase of 3% to EUR27.1M, Spain segment increase of 5% to EUR250.2M, Europe/Middle East segment increase of 3% to EUR406.9M, Other Unallocated segment increase of 3% to EUR27.1M.

Equity composition

changed name from Laboratorios Almirall SA 5/2012, Scrip Issue, 1 new share for every 36 shares held (Factor: 1.02778).5/2013, Scrip Issue, 1 new share for every 68 shares held (Factor: 1.01471).5/2019, Scrip Issue, 1 new share for every 74 shares held (Factor: 1.01351).